Compare GSK plc (GSK) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Intuitive Surgical, Inc. — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Intuitive Surgical, Inc. trades at $360 (market cap $137.76B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and GSK plc pays a 3.49% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| GSK | ISRG | |
|---|---|---|
Market Cap | $101.34B | $137.76B |
Sector | Health | Health |
52-Week High | $61.18 | $592.85 |
52-Week Low | $36.20 | $379.50 |
Enterprise Value | $121.95B | $133.24B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Intuitive Surgical (ISRG) trades at $399.75, up 5.34% today, but remains 25% below its 52-week high amid 2026 weakness. The stock shows bearish technical signals with key resistance near $402, while fundamentals remain strong with consistent revenue growth to $10.06B in 2025 and a 28.15% net margin. Recent quarters have seen earnings beats, with Q2 2026 results due July 16. Analyst sentiment is predominantly bullish with a $552.36 price target, though competition concerns persist.
Outlook: Long-term growth prospects in robotic surgery are compelling, supported by da Vinci 5 adoption and AI integration. Near-term risks include margin pressure and competitive threats. The stock offers potential upside if Q2 earnings beat expectations, but volatility may continue until growth catalysts materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
